Boston/Shanghai

June 12, 2023 - Eccogene, Inc.

The round was led by New Alliance Capital and Zhangkeherun Venture Capital, with participation from new investors Rockbleu Capital, Royal Fund, Zhuhai Huajin Capital, and Elikon Venture, and continued support from existing investors Delos Global Investment Fund, SIP Oriza Seed Fund, and CTS Capital. The funds raised will be used to support Eccogene's clinical-stage projects, including the Phase I trials of the small molecule GLP-1 receptor agonist ECC5004 for obesity and type 2 diabetes, as well as the Phase I trial of the THR-β full agonist ECC4703 for NASH and lipid disorders. Additionally, it will further advance Eccogene's pre-clinical project development in the fields of metabolism and immune-related diseases.

CEC Capital served as the financial advisor for Eccogene in this transaction.